Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X7KB
|
|||
| Former ID |
DAP000255
|
|||
| Drug Name |
Lisuride
|
|||
| Synonyms |
Lisurida; Lisuridum; Lysurid; Lysuride; Lisuride [INN]; Lysuride Hydrogen Maleate; Methylergol Carbamide; Arolac (TN); Cuvalit (TN); Dipergon (TN); Dopergin (TN); Dopergine (TN); Lisurida [INN-Spanish]; Lisuride (INN); Lisuridum [INN-Latin]; Lysenyl Forte (TN); Prolacam (TN); Revanil (TN); Lisuride Maleate (1:1); N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea; 3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1], [2] | |
| Fibrosis [ICD-11: GA14-GC01; ICD-10: L90.5; ICD-9: 709.2] | Phase 3 | [3] | ||
| Therapeutic Class |
Antiparkinson Agents
|
|||
| Company |
IVAX Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H26N4O
|
|||
| Canonical SMILES |
CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C
|
|||
| InChI |
1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1
|
|||
| InChIKey |
BKRGVLQUQGGVSM-KBXCAEBGSA-N
|
|||
| CAS Number |
CAS 18016-80-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979782, 8170644, 10321508, 11466134, 11467254, 11485767, 14827074, 16304643, 34671274, 46505557, 47216935, 47440423, 47515485, 47810926, 47885573, 48416176, 49698348, 50060231, 56464344, 57309764, 57310710, 76836308, 92125058, 96024822, 103408740, 103914001, 103952701, 104303892, 124749968, 124893624, 127339697, 127339698, 127339699, 127339700, 127339701, 127529620, 134337569, 134340181, 134340461, 135269077, 135650525, 137001465, 137225007, 142950042, 160963934, 163304387, 164761611, 179150133, 224890570, 226428258
|
|||
| ChEBI ID |
CHEBI:51164
|
|||
| ADReCS Drug ID | BADD_D01301 | |||
| SuperDrug ATC ID |
G02CB02; N02CA07
|
|||
| SuperDrug CAS ID |
cas=018016803
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 43). | |||
| REF 2 | Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol. 2006 Mar-Apr;29(2):80-6. | |||
| REF 3 | ClinicalTrials.gov (NCT00408915) Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion. U.S. National Institutes of Health. | |||
| REF 4 | Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9. | |||
| REF 5 | Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92. | |||
| REF 6 | Tolerance to some behavioural effects of lisuride, a dopamine receptor agonist, and reverse tolerance to others, after repeated administration. Neuropharmacology. 1985 Mar;24(3):199-206. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.